Jin Xie

1688 MEILING Avenue
Nanchang, 330004, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

The safety and efficacy of tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors combined with HAIC/TACE in the treatment of recurrent unresectable hepatocellular carcinoma.

The safety and efficacy of tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors combined with HAIC/TACE in the treatment of recurrent unresectable hepatocellular carcinoma.

Journal: BMC cancer

Published: April 02, 2024

Prognostic Value of Alpha-Fetoprotein in Unresectable Hepatocellular Carcinoma Treated with Hepatic Artery Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab.

Prognostic Value of Alpha-Fetoprotein in Unresectable Hepatocellular Carcinoma Treated with Hepatic Artery Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab.

Journal: Journal of hepatocellular carcinoma

Published: March 13, 2024

AURKB targets DHX9 to promote hepatocellular carcinoma progression via PI3K/AKT/mTOR pathway.

AURKB targets DHX9 to promote hepatocellular carcinoma progression via PI3K/AKT/mTOR pathway.

Journal: Molecular carcinogenesis

Published: September 03, 2023

Pretreatment Neutrophil-to-Lymphocyte Ratio as Prognostic Biomarkers in Patients with Unresectable Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab.

Pretreatment Neutrophil-to-Lymphocyte Ratio as Prognostic Biomarkers in Patients with Unresectable Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab.

Journal: Journal of hepatocellular carcinoma

Published: July 24, 2023

Beneficial effects of maintaining liver function during hepatic arterial infusion chemotherapy combined with tyrosine kinase and programmed cell death protein-1 inhibitors on the outcomes of patients with unresectable hepatocellular carcinoma.

Beneficial effects of maintaining liver function during hepatic arterial infusion chemotherapy combined with tyrosine kinase and programmed cell death protein-1 inhibitors on the outcomes of patients with unresectable hepatocellular carcinoma.

Journal: BMC cancer

Published: January 08, 2023

Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?

Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?

Journal: Journal of hepatocellular carcinoma

Published: September 13, 2022

Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience.

Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience.

Journal: Frontiers in oncology

Published: July 27, 2022

Rare benign liver tumors that require differentiation from hepatocellular carcinoma: focus on diagnosis and treatment.

Rare benign liver tumors that require differentiation from hepatocellular carcinoma: focus on diagnosis and treatment.

Journal: Journal of cancer research and clinical oncology

Published: May 14, 2022

Nose-to-brain delivery of drug nanocrystals by using Ca2+ responsive deacetylated gellan gum based in situ-nanogel.

Nose-to-brain delivery of drug nanocrystals by using Ca2+ responsive deacetylated gellan gum based in situ-nanogel.

Journal: International journal of pharmaceutics

Published: August 22, 2020

Nose-to-Brain Delivery by Nanosuspensions-Based in situ Gel for Breviscapine.

Nose-to-Brain Delivery by Nanosuspensions-Based in situ Gel for Breviscapine.

Journal: International journal of nanomedicine

Published: June 12, 2020

Novel redispersible nanosuspensions stabilized by co-processed nanocrystalline cellulose-sodium carboxymethyl starch for enhancing dissolution and oral bioavailability of baicalin.

Novel redispersible nanosuspensions stabilized by co-processed nanocrystalline cellulose-sodium carboxymethyl starch for enhancing dissolution and oral bioavailability of baicalin.

Journal: International journal of nanomedicine

Published: January 19, 2019

Redispersible Pickering emulsion powder stabilized by nanocrystalline cellulose combining with cellulosic derivatives.

Redispersible Pickering emulsion powder stabilized by nanocrystalline cellulose combining with cellulosic derivatives.

Journal: Carbohydrate polymers

Published: November 20, 2018

Showing 1-12 of 18

Last Updated: 09/26/2026